Fig. 5From: Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practiceVisual acuity (VA) of the ranibizumab (RBZ) poor responder patients after the 3rd injection of RBZ (mean: 0.62 ± 0.33 logMAR) and after the 3rd injection of aflibercept (AFL) (mean: 0.64 ± 0.44 logMAR)Back to article page